

# **Tebanicline (hydrochloride)**

# Catalog No: tcsc6400

Available Sizes

Size: 5mg		
Size: 10mg		
Size: 25mg		
Size: 50mg		
<b>Size:</b> 100mg		
Specifications		
<b>CAS No:</b> 203564-54-9		
Formula:		

 $C_9H_{12}CI_2N_2O$ 

Pathway: Neuronal Signaling;Membrane Transporter/Ion Channel

**Target:** nAChR;nAChR

### Purity / Grade:

>98%

Solubility: DMSO :  $\geq$  34 mg/mL (144.61 mM)

#### **Alternative Names:**

Ebanicline hydrochloride; ABT-594 hydrochloride

Copyright 2021 Taiclone Biotech Corp.



#### **Observed Molecular Weight:**

235.11

## **Product Description**

Tebanicline hydrochloride (ABT594 hydrochloride) is a **nAChR** modulator with potent, orally effective analgesic activity. It inhibits the binding of cytisine to  $\alpha 4\beta 2$  neuronal nAChRs with a **K**<sub>i</sub> of 37 pM.

IC50 & Target: Ki: 37 pM (nAChR)<sup>[1]</sup>

*In Vitro:* Tebanicline is a novel, potent cholinergic nAChR ligand with analgesic properties that shows preferential selectivity for neuronal nAChRs. It inhibits the binding of cytisine to  $\alpha4\beta2$  neuronal nAChRs with a K<sub>i</sub> of 37 pM. Functionally, tebanicline is an agonist. At the transfected human  $\alpha4\beta2$  neuronal nAChR in K177 cells, with increased <sup>86</sup>Rb<sup>+</sup> efflux as a measure of cation efflux, ABT-594 has an EC<sub>50</sub> value of 140 nM with an intrinsic activitycompared with (–)-nicotine of 130%; at the nAChR subtype expressed in IMR-32 cells, an EC<sub>50</sub> of 340 nM; at the F11 dorsal root ganglion cell line, an EC<sub>50</sub> of 1220 nM; and via direct measurement of ion currents, an EC<sub>50</sub> value of 56,000 nM at the human  $\alpha7$  homo-oligimeric nAChR produced in oocytes<sup>[1]</sup>

*In Vivo:* Tebanicline is a potent antinociceptive agent with full efficacy in models of acute and persistent pain and that these effects are mediated predominately by an action at central neuronal nAChRs<sup>[2]</sup>. Tebanicline produces significant antinociceptive effects in mice against both acute noxious thermal stimulation. ABT-594 is orally active, but 10-fold less potent by this route than after i.p. administration. The antinociceptive effect of ABT-594 is prevented, but not reversed, by the noncompetitive neuronal nicotinic acetylcholine receptor antagonist<sup>[3]</sup>. Tebanicline has antinociceptive effects in rat models of acute thermal, persistent chemical, and neuropathic pain. Direct injection of tebanicline into the nucleus raphe magnus (NRM) is antinociceptive in a thermal threshold test and destruction of serotonergic neurons in the NRM attenuates the effect of systemic tebanicline<sup>[4]</sup>.





All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.